Post-earnings recap
Reported
Thu, Aug 3, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.58%, possibly due to overall market conditions or investor sentiment. The lack of revenue data and guidance may leave investors uncertain about the company's immediate future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | -1.91% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to long-term goals.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on its long-term growth strategy despite the current EPS miss.